A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

Inclusion Criteria: * Healthy adults aged ≥ 19 and ≤ 45 years at the time of screening visit * BMI of ≥ 18.0 and ≤ 27.0 kg/m2 at the time of screening visit * Clinically confirmed as healthy based on the medical history, physical examination, vital signs, electrocardiography (ECG), and proper laboratory tests (Subjects with values out of the normal range may participate in the study if they are deemed clinically insignificant by the investigator.) * Agree to use medically acceptable methods of contraception by participant, his/her spouse, or partner and not to donate sperm or oocyte from the date of the first dose of the investigational product (IP) until 90 days after the last dose of the IP * Examples of medically acceptable methods of contraception * Females (females who use oral hormonal contraceptives and subcutaneous hormonal contraceptive implants may be excluded from the study) * Use of an intrauterine device with a proven pregnancy failure rate * Use of barrier method with spermicide * Surgical sterilization (salpingectomy/tubal ligation, hysterectomy, etc.) * Males * Use of barrier method with spermicide * Surgical sterilization (vasectomy, vasoligation, etc.) * Voluntarily decided to participate in the study and provided written consent to comply with the protocol Exclusion Criteria: * Current or history of a clinically significant hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, or cardiovascular d…